FRAGMENT BASED DRUG DISCOVERY (HB 2015)

ISBN 10: 1849739080 / ISBN 13: 9781849739085

Published by Royal Society of Chemistry, 2015

Brand New Original US Edition. Customer service! Satisfaction Guaranteed. Seller Inventory # ASNNN-59700

Synopsis:

This book will prove to be an invaluable resource for medicinal chemists working in academia and industry, as well as anyone interested in drug discovery techniques.

About the Author: Daniel A. Erlanson is the co-founder of Carmot Therapeutics, a small-molecule drug discovery company applying fragment-based approaches to a variety of therapeutic targets. Prior to Carmot, Dr. Erlanson spent a decade developing fragment-based drug discovery technologies at Sunesis Pharmaceuticals, where he worked since the company's inception. Before joining Sunesis, he was an NIH postdoctoral fellow with Dr. James A. Wells at Genentech. Dr. Erlanson earned his Ph.D. in chemistry from Harvard University in the laboratory of Gregory L. Verdine and his B.A. in chemistry from Carleton College. Wolfgang Jahnke is a Senior Research at the Novartis Institutes for Biomedical Research in Basel, Switzerland, where he leads the Fragment-Based Screening technology platform. He has received several honors, among them the appointment as Scientific Expert, and the Leading Scientist Award. Dr. Jahnke received his PhD from the TU Munchen, working with Horst Kessler on the development and application of novel NMR methods. Prior to joining Novartis, he worked with Peter Wright at the Scripps Research Institute in La Jolla.

Bibliographic Details

Title: FRAGMENT BASED DRUG DISCOVERY (HB 2015)
Publisher: Royal Society of Chemistry
Publication Date: 2015
Binding: Hardcover
Condition: New